Hasty OK of costly,
unproven Alzheimers’ drug
draws intense scrutiny
Three months ago the Food and Drug Administration – in a move that took many by surprise – granted “accelerated approval” for a wildly expensive but unproven new drug to treat Alzheimer’s disease.

Acting FDA Director Dr. Janet Woodcock
The move has been followed by a cascading series of protests and intense scrutiny.
The drug, Aducanumab (branded Aduhelm for marketing) was developed by Biogen Inc. It will cost patients about $56,000 per year. FDA approval could cost Medicare billions.
Two House committees have already launched probes of the approval process. Even the FDA acting director has asked the HHS inspector general to investigate.
The multiple probes indicate something serious is amiss. What is already known stinks to high heaven!
Read the rest of this entry »